Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$22.06 -1.6%	$20.87	$14.40 ▼ $47.00	$1.49B	1.13	968,074 shs	745,827 shs
DVAX Dynavax Technologies	$10.94 +2.1%	$10.13	$9.22 ▼ $14.63	$1.29B	1.03	2.14 million shs	1.06 million shs
INVA Innoviva	$19.50 -0.4%	$19.91	$16.67 ▼ $22.00	$1.23B	0.37	713,286 shs	632,095 shs
LXRX Lexicon Pharmaceuticals	$1.23	$0.80	$0.28 ▼ $2.45	$444.64M	1.13	6.89 million shs	3.97 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-1.56%	-5.57%	+7.61%	+13.77%	-39.99%
DVAX Dynavax Technologies	+2.05%	+1.86%	+9.51%	+2.05%	+6.73%
INVA Innoviva	-0.36%	-0.41%	-7.14%	+5.41%	+13.44%
LXRX Lexicon Pharmaceuticals	0.00%	+4.24%	+64.00%	+92.94%	-38.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	2.1413 of 5 stars	4.4	1.0	0.0	2.5	0.0	0.0
DVAX Dynavax Technologies	4.4631 of 5 stars	3.3	2.0	4.7	3.1	1.7	1.9
INVA Innoviva	4.5122 of 5 stars	3.5	0.0	4.2	2.7	1.7	3.1
LXRX Lexicon Pharmaceuticals	2.3379 of 5 stars	3.2	3.0	0.0	1.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.89	Moderate Buy	$50.11	127.16% Upside
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.00	119.38% Upside
INVA Innoviva	3.00	Buy	$40.33	106.84% Upside
LXRX Lexicon Pharmaceuticals	2.40	Hold	$3.67	198.10% Upside

Current Analyst Ratings Breakdown

Latest LXRX, CLDX, DVAX, and INVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
7/14/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
7/11/2025	INVA Innoviva	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
6/24/2025	LXRX Lexicon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/7/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $31.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/28/2025	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.02M	208.60	N/A	N/A	$11.26 per share	1.96
DVAX Dynavax Technologies	$277.25M	4.74	$0.16 per share	67.70	$4.54 per share	2.41
INVA Innoviva	$358.71M	3.41	$3.42 per share	5.71	$11.03 per share	1.77
LXRX Lexicon Pharmaceuticals	$31.08M	14.31	N/A	N/A	$0.40 per share	3.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$157.86M	-$2.70	N/A	N/A	N/A	-2,366.07%	-23.46%	-22.35%	8/6/2025 (Estimated)
DVAX Dynavax Technologies	$27.31M	-$0.52	N/A	22.33	N/A	-20.39%	3.59%	2.20%	8/5/2025 (Estimated)
INVA Innoviva	$23.39M	-$1.01	12.88	12.58	N/A	-16.15%	15.77%	8.41%	7/30/2025 (Estimated)
LXRX Lexicon Pharmaceuticals	-$200.40M	-$0.51	0.00	N/A	N/A	-568.04%	-103.16%	-54.95%	7/30/2025 (Estimated)

Latest LXRX, CLDX, DVAX, and INVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CLDX Celldex Therapeutics	-$0.86	N/A	N/A	N/A	$1.13 million	N/A
8/7/2025	Q2 2025	LXRX Lexicon Pharmaceuticals	-$0.07	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	DVAX Dynavax Technologies	$0.12	N/A	N/A	N/A	$87.55 million	N/A
7/30/2025	Q2 2025	INVA Innoviva	$0.43	N/A	N/A	N/A	$87.10 million	N/A
5/13/2025	Q1 2025	LXRX Lexicon Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	$1.26 million	$1.26 million
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/7/2025	Q1 2025	INVA Innoviva	N/A	$0.25	N/A	-$0.74	N/A	$88.63 million
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	-$0.11	-$0.14	-$0.77	$70.01 million	$68.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	21.67	21.67
DVAX Dynavax Technologies	0.49	11.93	10.84
INVA Innoviva	0.40	2.48	2.30
LXRX Lexicon Pharmaceuticals	0.48	2.22	2.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
DVAX Dynavax Technologies	96.96%
INVA Innoviva	99.12%
LXRX Lexicon Pharmaceuticals	74.70%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	4.40%
DVAX Dynavax Technologies	2.98%
INVA Innoviva	2.25%
LXRX Lexicon Pharmaceuticals	13.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.46 million	Optionable
DVAX Dynavax Technologies	350	120.08 million	116.50 million	Optionable
INVA Innoviva	100	62.78 million	61.36 million	Optionable
LXRX Lexicon Pharmaceuticals	140	361.49 million	311.25 million	Optionable

LXRX, CLDX, DVAX, and INVA Headlines

Recent News About These Companies

H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX)

July 20 at 2:34 AM | insidermonkey.com

H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX)

July 20 at 2:03 AM | msn.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 6.6% Higher - Should You Buy?

July 18, 2025 | marketbeat.com

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the ...

July 18, 2025 | bakersfield.comB

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

July 18, 2025 | globenewswire.com

Analysts Set Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) PT at $3.67

July 13, 2025 | americanbankingnews.com

Lexicon Pharmaceuticals, Inc. (LXRX) - Yahoo Finance

July 12, 2025 | finance.yahoo.com

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Average Rating of "Hold" by Brokerages

July 10, 2025 | marketbeat.com

Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension

July 3, 2025 | tipranks.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?

July 2, 2025 | marketbeat.com

While institutions own 28% of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), private equity firms are its largest shareholders with 48% ownership

June 30, 2025 | finance.yahoo.com

LXRX - Lexicon Pharmaceuticals Inc Price vs Fair Value - Morningstar

June 26, 2025 | morningstar.comM

Lexicon Pharmaceuticals' (LXRX) Buy Rating Reiterated at HC Wainwright

June 24, 2025 | marketbeat.com

H.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stock

June 24, 2025 | investing.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200 Day Moving Average - Here's What Happened

June 24, 2025 | marketbeat.com

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

June 23, 2025 | globenewswire.com

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

June 18, 2025 | globenewswire.com

Lexicon Pharmaceuticals surges 67% following InvestingPro's Fair Value signal

June 8, 2025 | investing.com

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential

May 21, 2025 | insidermonkey.com

Lexicon Pharmaceuticals’ Sotagliflozin: Promising Phase 3 Developments Justify Buy Rating

May 20, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX, CLDX, DVAX, and INVA Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$22.06 -0.35 (-1.56%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$22.08 +0.02 (+0.07%)

As of 07/21/2025 04:15 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Dynavax Technologies NASDAQ:DVAX

$10.94 +0.22 (+2.05%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$10.86 -0.08 (-0.73%)

As of 07/21/2025 07:35 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Innoviva NASDAQ:INVA

$19.50 -0.07 (-0.36%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$19.50 +0.00 (+0.03%)

As of 07/21/2025 06:51 PM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.23 0.00 (0.00%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$1.25 +0.02 (+1.63%)

As of 07/21/2025 07:56 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time